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EDITORIAL

Phosphate Enters the Syzygy

T

he elaboration of the interactions among calcium,
phosphate, and parathyroid hormone (PTH) has
somewhat followed the evolution of astronomy. Ptolemy
proposed that the sun revolved about the earth, and his
geocentric view of our solar system was accepted for centuries. The proof of a heliocentric system of circumscribed
elliptical not circular orbits required the efforts of Copernicus, Galileo, and Kepler. Today, with superior instrumentation, contemporary cosmologists generate and test
hypothesis at comparative light speed. Similarly, the roles
played by calcium and phosphate, under the gravitational influence of PTH, have assumed primacy at various
points during the elucidation of the pathogenesis of
chronic kidney disease-mineral and bone disorder
(CKD-MBD). In this phosphocentric issue of Advances in
Chronic Kidney Disease, our Guest Editors, Eleanor Lederer
and Moshe Levi, have coordinately integrated inorganic
phosphate into the expansive pathophysiology of
CKD-MBD.
The authors recruited for this task multiple scientific
observations gleaned with the aid of molecular tools to
make their points. With these enhancements has come
a renewed interest in the field, and the rarest of celestial
events has occurred—the syzygy—an alignment of the
spheres of calcium, phosphate, and PTH. The Guest
Editors had from the outset mapped out a course of alignment for the authors who would reconcile much of what
we have postulated and learned in the past half decade
regarding the pathogenesis of CKD-MBD, with inorganic
phosphate as the central theme. The authors delineate
a new presentation of the galaxy of CKD-MBD and introduce new players within this particular cosmos of CKD.
The basic tenets still hold. As glomerular filtration
declines, phosphate retention occurs and is toxic, exerting
diverse effects on vascular smooth muscle cells, among
others. Calcium, which had originally been at
approximately the same plasma molarity as ionized calcium, is now silently complexed by a rising serum phosphate. This occurs in concert with a corresponding
decline in fetuin levels. Fetuin, also termed a2-Heremans-

Schmid glycoprotein, maintains phosphate in a quasistable complex with calcium, thus inhibiting untoward
calcification.1 Even mild disruption of this equilibrium permits fusion of calcium and phosphate and underpins the
beginning of the cardiovascular risk associated with
advancing CKD, namely, de novo and accelerated calcification of the vasculature. This response is abetted by the process of hemodialysis, and adjustments in dialysate baths
are required. These events likely require phosphate ‘‘sensing,’’ and involve evolutionary conservation of these
molecular sensors from their prokaryotic origins.2 The
intestinal lumen exhibits phosphate sensing, and phosphaturia is initiated in advance of absorptive hyperphosphatemia, sentiently pre-empting elevations of PTH. Activation
of these sensors deploys multiple downstream events
involving cellular metabolism and likely those related to
differentiation and proliferation. However, all of this
occurs despite the compensatory onset of secondary hyperparathyroidism onset of secondary hyperparathyroidism
and elevation of phosphatonins.3
Like black holes, phosphatonin effects were theorized
first and then discovered because the entity itself
remained ethereal. To have characterized them as nebulous would have been generous. Later than sooner, they
were found and the family of phosphatonins has been partially described (see Table 1 by Razzaque, p. 96). The most
fully characterized phosphatonin is fibroblast growth
factor 23 (FGF-23) and is elaborated by osteocytes and
osteoblasts.4 FGF-23 appears early during the course of
CKD and its secretion is promoted by hyperphosphatemia
and 1,25(OH)2D3. FGF-23 also increases osteoblastic
transcriptomal activity, thus rendering a calcium-laden
phenotype that translates clinically as impaired vascular
compliance and heightened pulse wave velocity,
secondary to vascular structural alterations (eg,
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osteochondrogenic transformation, calcification, and elastic degradation) that give rise to windkessels.
FGF-23 downregulates proximal tubular 1-alphahydroxylation of 25(OH)D3 in contradistinction to PTH
and, working in conjunction with klotho, amplifies
PTH’s effects on the apical, proximal tubular sodiumdependent phosphate cotransporter (see Cover of this
issue).5 This family of phosphate co-transporters includes
Npt2a, Npt2c, and PiT2 and is regulated by physiological
stimuli that include PTH, glucocorticoids, steroids, vitamin D, and endocrine hormones, among others.
In addition, FGF-23 is also positively regulated by
dietary phosphate consumption and active vitamin 1,25
(OH)2D, recapitulating and reaffirming the postulates of
those who expounded on the primacy of phosphate
and whose experimental instruments were on par with
refractor telescopes of the ancient astronomers. Significantly, dietary privation of phosphate increases the lifespan of klotho- and FGF-23-knockout mice.6 However,
the klotho co-receptor, somewhat portrayed as the binary
star of FGF-23, may escape the orbit of FGF-23 and act
independently of it, for example, during regulation of
the subfamily V transient receptor potential cation channel. Unsurprisingly, FGF-23 like its inducer, phosphate, is
now associatively coupled to future adverse cardiovascular events and kidney disease progression.7 Please recall
that despite a worldwide dearth of phosphate, dietary
phosphate is in surfeit, surreptitiously yet robustly entering our food chain as United States Department of
Agriculture-unlabeled food preservatives.7 Perhaps, in
the future, regulation of gut sodium-dependent phosphate cotransporter, Npt2b, will be possible, thereby offsetting to some extent our inability to enforce dietary
phosphate restriction.
However, as clearly pointed out by Kendrick and colleagues, we have excellent epidemiological data on elevated phosphate levels and excessive cardiovascular
events that do not translate directly to precise consensusbased clinical practice guidelines.8 Are we light-years
away because hard endpoint analysis and randomized,
controlled clinical trials that provide this information
remain as distant as the stars? For the present, trend analysis of the parameters of CKD-MBD is recommended by
KDIGO rather than therapy based on isolated calcium,
phosphate, and intact PTH levels.

To conclude, as the multiple efforts of the astronomers
reconciled the fundamental truths of our solar system, so
too have our authors reconciled some of the mysteries of
the pathobiology of CKD-MBD. With time, the model
changed, and not gradually, at times propelled forward
by ideas considered heretical (Galileo) or revolutionary
in scope. The Guest Editors have assembled a group of
papers that have aligned the interdependent forces of calcium, phosphate, and PTH axis. None of them is ‘‘fixed in
the sky,’’ and there is continual interchange among them.
Calcium and PTH have since long been accorded their
dues and finally, inorganic phosphate claims its place
among the members of this syzygy. With time and greater
accrual of knowledge regarding the phosphatonins, this
alignment will become even more precise.
Finally, let us return to our earthly plane to hail our
annual nephrologic event, World Kidney Day—held
every year on the second Thursday of March. We, along
with our international colleagues, celebrate this day
that acknowledges our discipline’s galaxy in the universe
of medicine. Please turn the page for Dr. William
Couser’s editorial.
Jerry Yee, MD
Editor
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